Olivia Rensing

Olivia Rensing

Auto-generated profile, based on publicly available information

Olivia Rensing

Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2024 in Cancer Immunology Research
Verified
Journal Article
Open access
PDF file
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Reovirus type 3 Dearing (Reo), manufactured for clinical application as pelareorep, is an attractive anticancer agent under evaluation in multiple phase 2 clinical trials for the treatment of solid tumors. It elicits its anticancer efficacy by inducing both oncolysis and intratumoral T-cell influx. Because most people have been preexposed to Reo, neutralizing antibodies (NAb) are prevalent in patients with cancer and might present a barrier to effective Reo therapy. Here, we tested serum of patients with cancer and healthy controls (n = 100) and confirmed that Reo NAbs are present in >80% of individuals. To investigate the effect of NAbs on both the oncolytic and the immunostimulatory efficacy of Reo, we established an experimental mouse model with Reo preexposure. The presence of preexposure-induced NAbs reduced Reo tumor infection and prevented Reo-mediated control of tumor growth after intratumoral Reo administration. In B cell–deficient mice, the lack of NAbs provided enhanced tumor growth control after Reo monotherapy, indicating that NAbs limit the oncolytic capacity of Reo. In immunocompetent mice, intratumoral T-cell influx was not affected by the presence of preexposure-induced NAbs and consequently, combinatorial immunotherapy strategies comprising Reo and T-cell engagers or checkpoint inhibitors remained effective in these settings, also after a clinically applied regimen of multiple intravenous pelareorep administrations. Altogether, our data indicate that NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity. Given the high prevalence of seropositivity for Reo in patients with cancer, our data strongly advocate for the application of Reo as part of T cell–based immunotherapeutic strategies.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S4. Neutralizing antibodies are required to prevent Reo-induced weight loss and viremia.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Reovirus type 3 Dearing (Reo), manufactured for clinical application as pelareorep, is an attractive anticancer agent under evaluation in multiple phase 2 clinical trials for the treatment of solid tumors. It elicits its anticancer efficacy by inducing both oncolysis and intratumoral T-cell influx. Because most people have been preexposed to Reo, neutralizing antibodies (NAb) are prevalent in patients with cancer and might present a barrier to effective Reo therapy. Here, we tested serum of patients with cancer and healthy controls (n = 100) and confirmed that Reo NAbs are present in >80% of individuals. To investigate the effect of NAbs on both the oncolytic and the immunostimulatory efficacy of Reo, we established an experimental mouse model with Reo preexposure. The presence of preexposure-induced NAbs reduced Reo tumor infection and prevented Reo-mediated control of tumor growth after intratumoral Reo administration. In B cell–deficient mice, the lack of NAbs provided enhanced tumor growth control after Reo monotherapy, indicating that NAbs limit the oncolytic capacity of Reo. In immunocompetent mice, intratumoral T-cell influx was not affected by the presence of preexposure-induced NAbs and consequently, combinatorial immunotherapy strategies comprising Reo and T-cell engagers or checkpoint inhibitors remained effective in these settings, also after a clinically applied regimen of multiple intravenous pelareorep administrations. Altogether, our data indicate that NAbs hamper the oncolytic efficacy of Reo, but not its immunotherapeutic capacity. Given the high prevalence of seropositivity for Reo in patients with cancer, our data strongly advocate for the application of Reo as part of T cell–based immunotherapeutic strategies.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S3. Kinetics of neutralizing antibodies after preexposure.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S14. Frequency of circulating phagocytic myeloid cells during Reo preexposure.

4 March 2024
Verified
Other
Open access
CGChristianne Groeneveldt
Christianne Groeneveldt
PKPriscilla Kinderman
Priscilla Kinderman
LGLisa Griffioen
Lisa Griffioen
OROlivia Rensing
Olivia Rensing
CLCamilla Labrie
Camilla Labrie
NMNadine van Montfoort
Nadine van Montfoort
Figure S12. Influx of immune cells after intratumoral Reo or VSV treatment of KPC3 tumors in Reo-preexposed or VSV-preexposed mice.